Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Baxdrostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat

    21 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/21/2612072/0/en/CinCor-Pharma-Announces-Receipt-of-Minutes-from-End-of-Phase-2-Meeting-with-the-U-S-Food-and-Drug-Administration-on-Planned-Phase-3-Program-of-Baxdrostat.html

    GLOBENEWSWIRE
    21 Feb 2023
    Share Share
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal

    10 Jan 2023

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html

    PRESS RELEASE
    10 Jan 2023
    Share Share
    CinCor's hypertension drug loses halo after phase 2 fail
    CinCor's hypertension drug loses halo after phase 2 fail

    29 Nov 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/cincors-hypertension-drug-loses-its-halo-after-phase-2-fail-plunging-stock-44

    James Waldron FIERCEBIOTECH
    29 Nov 2022
    Share Share
    CinCor Pharma Announces Publication in the NEM of Phase 2 BrigHtn Data
    CinCor Pharma Announces Publication in the NEM of Phase 2 BrigHtn Data

    07 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/07/2550309/0/en/CinCor-Pharma-Announces-Publication-in-the-New-England-Journal-of-Medicine-of-Phase-2-BrigHtn-Data-on-Selective-Aldosterone-Synthase-Inhibitor-Baxdrostat-in-Treatment-Resistant-Hyp.html

    GLOBENEWSWIRE
    07 Nov 2022
    Share Share
    CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat
    CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat

    25 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/25/2540780/0/en/CinCor-Pharma-Announces-Presentation-of-Phase-1-Clinical-Data-for-Baxdrostat-at-the-Upcoming-American-Society-of-Nephrology-Kidney-Week-2022.html

    GLOBENEWSWIRE
    25 Oct 2022
    Share Share
    CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat
    CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat

    12 Oct 2022

    // CINCOR

    https://www.cincor.com/news-releases/news-release-details/cincor-pharma-announces-oral-presentation-phase-1-data

    CINCOR
    12 Oct 2022
    Share Share